CAPITOL HEALTH LIMITED (CAJ)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CAJ - CAPITOL HEALTH LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.36
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.205

27 Sep
2023

-0.005

OPEN

$0.21

-2.38%

HIGH

$0.21

248,488

LOW

$0.20

TARGET
$0.293 43.1% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLA . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL . SLA .
FNARENA'S MARKET CONSENSUS FORECASTS
CAJ: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 1.1 1.0 xxx
DPS (cps) xxx 1.0 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx 0.0% 0.0% xxx
PE Ratio xxx N/A 21.1 xxx
Dividend Yield xxx N/A 5.0% xxx
Div Pay Ratio(%) xxx N/A 105.3% xxx

Dividend yield today if purchased 3 years ago: 3.85%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 21/09 - ex-div 0.5c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-1.1
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx209.6 M
Book Value Per Share xxxxxxxxxxxxxxx12.9
Net Operating Cash Flow xxxxxxxxxxxxxxx37.5 M
Net Profit Margin xxxxxxxxxxxxxxx-5.44 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-7.85 %
Return on Invested Capital xxxxxxxxxxxxxxx-4.70 %
Return on Assets xxxxxxxxxxxxxxx-3.87 %
Return on Equity xxxxxxxxxxxxxxx-7.85 %
Return on Total Capital xxxxxxxxxxxxxxx6.08 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx10.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx12 M
Long Term Debt xxxxxxxxxxxxxxx123 M
Total Debt xxxxxxxxxxxxxxx135 M
Goodwill - Gross xxxxxxxxxxxxxxx157 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx19 M
Price To Book Value xxxxxxxxxxxxxxx2.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx16.8 M
Capex % of Sales xxxxxxxxxxxxxxx8.04 %
Cost of Goods Sold xxxxxxxxxxxxxxx172 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx22 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

25/08/2023

1

Outperform

$0.30

46.34%

Capitol Health's FY23 result met underlying EBITDA guidance provided in June, and outpaced Macquarie's forecast by 1%, thanks to a stronger than expected recovery in organic revenue.

On the downside, elevated operating expenditure hit earnings (EBITDA) margins as high labour, recruitment and occupancy costs took their toll.

The broker expects continued strong growth in organic revenue in FY24 but spies headwinds from GP attendance which is slower to recover from covid (down -27% on pre-covid), noting the company gains 80% of referrals from GPs. It also expects continued cost growth.

EPS forecasts fall -4% in FY24, rise 1% in FY25 and 5% in FY25.

Outperform rating and 30c target price retained.

FORECAST
Macquarie forecasts a full year FY24 dividend of 1.00 cents and EPS of 1.10 cents.
Macquarie forecasts a full year FY25 dividend of 0.80 cents and EPS of 1.50 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

CAJ STOCK CHART

FNArena News on CAJ

1
Rudi’s View: Outlook Negative, With Plenty Of Silver Linings

Sep 06 2023 - Rudi's View
2
Australian Broker Call *Extra* Edition – Aug 31, 2023

Aug 31 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 30, 2023

Aug 30 2023 - Daily Market Reports
4
FNArena Corporate Results Monitor – 25-08-2023

Aug 25 2023 - Australia
5
Rudi’s View: Helia, Hub24, Judo, QBE, ResMed, Santos, Telstra & Xero

Aug 09 2023 - Rudi's View

Latest Healthcare services News

1
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
2
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
3
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
4
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
5
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
6
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
7
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
8
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
9
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
10
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia